Solid Biosciences shares plummet as gene therapy trial halted againAnalysts, Bleeding, Clinical Hold, Duchenne Muscular Dystophy (DMD), Gene Therapy, Men, Muscle Wasting Disorders, Platelet Count, R&D, Red Blood CellShares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years. Read more November 12, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-11-12 07:07:152019-11-12 13:19:53Solid Biosciences shares plummet as gene therapy trial halted again
